---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273250"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:41:33.680456+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apogee Q3 net loss $65M; APG333 half-life ~55 days supports quarterly dosing; cash $913M, runway into 2H 2028

## Summary
- Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.
- APG333 Phase 1 data: half-life ~55 days, biomarker suppression for 6 months, well tolerated up to 1000 mg; supports quarterly or better dosing for APG273 co-formulation.
- APG777 readouts accelerated: Phase 1b asthma data Q1 2026; APEX Part A 52-week data Q1 2026; APEX Part B 16-week data Q2 2026; Phase 3 start 2H 2026.
- APG279 (APG777+APG990) head-to-head vs DUPIXENT in AD interim readout expected 2H 2026.
- Cash runway extended into 2H 2028 through Phase 3 topline data for APG777.

## SEC filing metadata
- accession: 0001193125-25-273250
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000119312525273250/0001193125-25-273250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000119312525273250/apge-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273250
- JSON: https://secwatch.observer/filing/0001193125-25-273250.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.